Mohammad A. Rafi, Yadollah Omidi* 
|
Francesco Angelini*, Vittoria Ionta, Fabrizio Rossi, Fabio Miraldi, Elisa Messina, Alessandro Giacomello
|
Nasrollah Jabbari , Maryam Feghhi, Omid Esnaashari, Hamid Soraya, Jafar Rezaie*
Treatment of MCF-10a, MCF-7, and MDA-MD-231 cells with Gallic acid resulted in inhibition in the activity of the exosomal secretory pathway. Gallic acid can decrease the expression of genes involved in exosomes biogenesis (Alix and CD63) and secretion (Rab proteins). In addition, Gallic acid can change the expression of autophagy markers (LC3 and P62) in these cells. MVB: multivesicular body.
|
Yalda Rahbar Saadat , Jaleh Barar*
Jaleh Barar (PharmD, Ph.D.) is a Full Professor at the Faculty of Pharmacy, Tabriz University of Medical Sciences. Professor Barar is working on various aspects of pharmaceutical cell biology with particular emphasis on the development of novel drug delivery/targeting systems. Dr Barar is listed among top 1% of world scientists based on ESI ranking system.
|
Yuri Yu. Shchegolev , Danila V. Sorokin, Alexander M. Scherbakov* , Olga E. Andreeva , Diana I. Salnikova , Ekaterina I. Mikhaevich , Margarita V. Gudkova , Mikhail A. Krasil’nikov
Prolonged cell treatment with mTOR inhibitor rapamycin leads to the development of resistance. Exosomes of resistant cells induce the resistance to rapamycin in the parent MCF-7cells. Exosome-induced resistance reproduces the changes revealed in the rapamycin-resistant cells, including the activation of ERK/AP-1.
|